Calidi Biotherapeutics
CLDI
10 hedge funds and large institutions have $3.54M invested in Calidi Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 20 closing their positions.
0.05% less ownership
Funds ownership: 0.05% → 0% (-0.05%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
58% less funds holding
Funds holding: 24 → 10 (-14)
70% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 20
91% less capital invested
Capital invested by funds: $39M → $3.54M (-$35.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$3.66M |
| 2 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$1.05M |
| 3 |
SAMC
Spectrum Asset Management (California)
Newport Beach,
California
|
+$696K |
| 4 |
RWI
Red Wave Investments
Dillsburg,
Pennsylvania
|
+$470K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$5.25M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$4.2M |
| 3 |
KL
KIM LLC
Wichita,
Kansas
|
-$3.74M |
| 4 |
6CM
683 Capital Management
New York
|
-$3.15M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.43M |
CLDI Hedge Fund Activity: Q3 2023 in Review
10 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q3 2023, worth a combined $3.54M — down 91% from $39M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CLDI and 6 opened new positions — a net loss of 14 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Meteora Capital, opening a new position worth an estimated $3.66M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $5.25M sold.
- 10 institutional investors held Calidi Biotherapeutics (CLDI) as of Q3 2023, down from 24 in Q2 2023.
- Funds reported $3.54M of Calidi Biotherapeutics stock for Q3 2023, down 91% quarter-over-quarter.
- 6 funds opened new Calidi Biotherapeutics positions in Q3 2023 and 20 closed out, a net change of -14 holders.
- The largest Calidi Biotherapeutics buyer in Q3 2023 was Meteora Capital, an estimated $3.66M added.
- The largest Calidi Biotherapeutics seller in Q3 2023 was Hudson Bay Capital Management, an estimated $5.25M sold.
Based on aggregated 13F filings for Q3 2023.